Evidence map›Paper›PMID 39376560›Full record

ArticleFrontiers in immunology2024

Increased peritoneal TGF-β1 is associated with ascites-induced NK-cell dysfunction and reduced survival in high-grade epithelial ovarian cancer.

Ralph J A Maas, Janneke S Hoogstad-van Evert, Iris M Hagemans, Jolanda Brummelman, Diede van Ens, Paul K J D de Jonge, Laura Hooijmaijers, Shweta Mahajan, Anniek B van der Waart, Charlotte K J C Hermans and 11 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Origin of Hypofunctional CD103European journal of immunology · 2025
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Ralph J A MaasLaboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Janneke S Hoogstad-van EvertLaboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Iris M HagemansLaboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Jolanda BrummelmanLaboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Diede van EnsLaboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Paul K J D de JongeLaboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Laura HooijmaijersLaboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Shweta MahajanLaboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Anniek B van der WaartLaboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Charlotte K J C HermansLaboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Janne de KleinLaboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Rob WoestenenkLaboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Antonius E van HerwaardenDiagnostic Laboratory - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Nicolaas P M SchaapDepartment of Hematology, Radboud University Medical Center, Nijmegen, Netherlands.
Somayeh RezaeifardLaboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Daniele V F TaurielloDepartment of Cell Biology, Radboud University Medical Center, Nijmegen, Netherlands.
Petra L M ZusterzeelDepartment of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, Netherlands.
Nelleke OttevangerDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.
Joop H JansenLaboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Willemijn Hobo *Laboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Harry Dolstra *Laboratory of Hematology - Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cell therapy represents an attractive immunotherapy approach against recurrent epithelial ovarian cancer (EOC), as EOC is sensitive to NK cell-mediated cytotoxicity. However, NK cell antitumor activity is dampened by suppressive factors in EOC patient ascites. Here, we integrated functional assays, soluble factor analysis, high-dimensional flow cytometry cellular component data and clinical parameters of advanced EOC patients to study the mechanisms of ascites-induced inhibition of NK cells. Using a suppression assay, we found that ascites from EOC patients strongly inhibits peripheral blood-derived NK cells and CD34+ progenitor-derived NK cells, albeit the latter were more resistant. Interestingly, we found that higher ascites-induced NK cell inhibition correlated with reduced progression-free and overall survival in EOC patients. Furthermore, we identified transforming growth factor (TGF)-β1 to correlate with ascites-induced NK cell dysfunction and reduced patient survival. In functional assays, we showed that proliferation and anti-tumor reactivity of CD34+ progenitor-derived NK cells are significantly affected by TGF-β1 exposure. Moreover, inhibition of TGF-β1 signaling with galunisertib partly restored NK cell functionality in some donors. For the cellular components, we showed that the secretome is associated with a different composition of CD45+ cells between ascites of EOC and benign reference samples with higher proportions of macrophages in the EOC patient samples. Furthermore, we revealed that higher TGF-β1 levels are associated with the presence of M2-like macrophages, B cell populations and T-regulatory cells in EOC patient ascites. These findings reveal that targeting TGF-β1 signaling could increase NK cell immune responses in high-grade EOC patients.

Indexed as

AscitesCarcinoma, Ovarian EpithelialKiller Cells, NaturalOvarian NeoplasmsTransforming Growth Factor beta1AgedFemaleHumansMiddle AgedNeoplasm GradingPyrazolesQuinolinesLY-2157299PyrazolesQuinolinesTGFB1 protein, humanTransforming Growth Factor beta1ascitesnatural killer (NK) cellsovarian cancerTGF-βtumor microenvironment

Identifiers

PMID39376560
PMCPMC11456434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.